Challenging a dogma: Antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis;Remise en question d'un dogme: Points de rupture des tests de sensibilité aux antimicrobiens de la Mycobacterium tuberc

Bulletin of the World Health Organization

Volumn 90, Issue 9, 2012, Pages 693-698

  Ängeby, Kristian ^a   Juréen, Pontus ^b   Kahlmeter, Gunnar ^c   Hoffner, Sven E ^b   Schönd, Thomas ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Swedish Institute for Communicable Disease Control   (Sweden)

^c Växjö Hospital   (Sweden)

^d KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CAPREOMYCIN; RIFABUTIN; RIFAMPICIN;

ANTIMICROBIAL ACTIVITY; CONCENTRATION (COMPOSITION); DISEASE CONTROL; DRUG RESISTANCE; INHIBITOR; TUBERCULOSIS;

ACCURACY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFACT; BACTERIAL GENE; CULTURE MEDIUM; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REPRODUCIBILITY; RPOB GENE; STRAIN DIFFERENCE; WILD TYPE;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

BACTERIA (MICROORGANISMS); FUNGI; MYCOBACTERIUM TUBERCULOSIS;

EID: 84865694488     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.11.096644     Document Type: Article

References (17)

1. Laszlo A, Rahman M, Espinal M, Raviglione M; WHO/IUATLD Network of Supranational Reference Laboratories. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD supranational reference laboratory network: five rounds of proficiency testing, 1994-1998. Int J Tuberc Lung Dis 2002;6:748-56.PMID:12234129
2. The programmatic management of drug-resistant tuberculosis - emergency update 2008. Geneva: World Health Organization; 2008. Available from: http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf [accessed 24 April 2012].
3. Kahlmeter G, Brown DF, Goldstein FW, MacGowan AP, Mouton JW, Odenholt I et al. European Committee on Antimicrobial Susceptibility Testing (EUCAST) technical notes on antimicrobial susceptibility testing. Clin Microbiol Infect 2006;12:501-3. doi:10.1111/j.1469-0691.2006.01454.x PMID:16700696
4. European Committee on Antimicrobial Susceptibility Testing[Internet]. Definitions of clinical breakpoints and epidemiological cut-off values. Växjö: EUCAST; 2012. Available from: http://www.srga.org/Eucastwt/eucastdefinitions.htm [accessed 24 April 2012].
5. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: Approved Standard M24-A. Wayne: National Committee for Clinical Laboratory Standards; 2003.
6. Guidelines for surveillance of drug resistance in tuberculosis. 4th ed. Geneva: World Health Organization; 2009. Available from: http://whqlibdoc.who.int/publications/2009/9789241598675_eng.pdf [accessed 24 April 2012].
7. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005;25:564-9. doi:10.1183/09031936.05.00111304 PMID:15738303
8. Iseman MD. A clinician's guide to tuberculosis. Philadelphia: Lippincott Williams & Wilkins; 2000.
9. Hoffner SE, Salfinger M. Ad fontes! Int J Tuberc Lung Dis 2010;14:260. PMID:20132612
10. Schön T, Juréen P, Giske CG, Chryssanthou E, Sturegård E, Werngren J et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 2009;64:786-93. doi:10.1093/jac/dkp262 PMID:19633001
11. Juréen P, Ängeby K, Sturegård E, Chryssanthou E, Giske CG, Werngren J et al. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J Clin Microbiol 2010;48:1853-8. doi:10.1128/JCM.00240-10 PMID:20237102
12. Ängeby KA, Jureen P, Giske CG, Chryssanthou E, Sturegård E, Nordval lM et al. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J Antimicrob Chemother 2010;65:946-52. doi:10.1093/jac/dkq091 PMID:20332195
13. Schön T, Juréen P, Chryssanthou E, Giske CG, Sturegård E, Kahlmeter G et al. Wild-type distributions of seven oral second line drugs against Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2011;15:502-9. doi:10.5588/ijtld.10.0238 PMID:21396210
14. Werngren J, Sturegård E, Juréen P, Ängeby K, Hoffner S, Schön T et al. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing. Antimicrob Agents Chemother 2012;56:1253-7. doi:10.1128/AAC.05894-11 PMID:22203587
15. Arendrup MC, Kahlmeter G, Rodriguez-Tudela JL, Donnelly JP. Breakpoints for susceptibility testing should not divide wild-type distributions of important target species. Antimicrob Agents Chemother 2009;53:1628-9. doi:10.1128/AAC.01624-08 PMID:19188378
16. Larsson C, Kanungo R, Kahlmeter G, Rao SR, Krantz I, Norrby SR et al. High frequency of multiresistant respiratory tract pathogens at community level in South India. Clin Microbiol Infect 1999;5:740-7. doi:10.1111/j.1469-0691.1999.tb00707.x
17. Sjölund M, Bengtsson S, Bonnedahl J, Hernandez J, Olsen B, Kahlmeter G. Antimicrobial susceptibility in Escherichia coli of human and avian origin-a comparison of wild-type distributions. Clin Microbiol Infect 2009;15:461-5. doi:10.1111/j.1469-0691.2009.02705.x PMID:19260874